IRCT20200809048342N3尚未招募2 期
Clinical Trial Phase IIa, on Amelioration of Decompensated Liver Cirrhosis with Mesenchymal Stem Cells-derived Exosomes
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Able to understand and willing to voluntarily sign an informed consent form (ICF) authorization.
- •Males or females between 18-75 years old with a clinically confirmed diagnosis of Liver cirrhosis with any etiology, except viral cirrhosis.
- •Child score class B or C.
排除标准
- •Known cardiovascular disease.
- •a) History of hepatocellular carcinoma (HCC). b) History of malignancy within the past 5 years or ongoing malignancy other than basal cell carcinoma, or resected noninvasive cutaneous squamous carcinoma at the time of Screening visit. c) Active, serious infections that require parenteral antibiotic or antifungal therapy within 30 days prior to Screening visit.
- •Females who are pregnant or breastfeeding.
- •Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents and immunomodulating agents (such as systemic corticosteroids, interleukins, interferons).
- •Use of any experimental medications within the last 6 months of Screening Visit.
- •Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements.
- •Weight loss of >5% within 6 months prior to Screening, based on subject's reporting.
- •Currently or participated in a weight loss program within the last 6 months.
- •Any history of bariatric surgery.
- •Diabetes mellitus Type I.
- •Daily alcohol intake >20 ml (2 units)/day for women and 30 ml (3 units)/day for men (on average), as per Alcohol Use Disorders Identification Test (AUDIT) questionnaire at Screening and plan to consume the same alcohol amount referenced above during the trial.
- •Use of any immunosuppressive medication, anti-inflammatory monoclonal antibody treatment, or chronic systemic corticosteroids >10 mg prednisone-equivalent concurrently or within 1 year prior to Screening.
- •Uncontrolled or clinically unstable thyroid disease, in the judgment of the Principal Investigator.
- •Uncontrolled arterial hypertension
- •Any severe, acute, or chronic medical or psychiatric condition that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the subject inappropriate for entry into this study
研究者
相似试验
进行中（未招募）
1 期
Clinical Trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19.EUCTR2020-001450-22-ESFundación de Investigación del Hospital Infantil Universitario Niño Jesús106
进行中（未招募）
1 期
Randomised clinical trial to test if silibinin administration can prevent the respiratory failure secondary to the COVID19 lung infection in oncologic patients.COVID19 respiratory failureEUCTR2020-001794-77-ESINSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA92
招募中
2 期
Cladribine therapy in MyastheniaMyasthenia gravis2024-517083-32-00Uniwersytet Medyczny W Lublinie200
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25
进行中（未招募）
2 期
Phase IIa study (doctor-led trial) for the efficacy and safety of SJP-0008 in central retinal artery occlusiocentral retinal artery occlusionJPRN-jRCT2021190013akazawa Toru20